title: Lichen planopilaris-like eruption during treatment with tyrosine kinase inhibitor nilotinib.
abstract: Tyrosine kinase inhibitors are effective as a target therapy for malignant neoplasms. Imatinib was the first tyrosine kinase inhibitor used. After its introduction, several other drugs have appeared with a similar mechanism of action, but less prone to causing resistance. Even though these drugs are selective, their toxicity does not exclusively target cancer cells, and skin toxicity is the most common non-hematologic adverse effect. We report an eruption similar to lichen planopilaris that developed during therapy with nilotinib, a second generation tyrosine kinase inhibitor, in a patient with chronic myeloid leukemia resistant to imatinib. In a literature review, we found only one report of non-scarring alopecia due to the use of nilotinib.
authors.affiliation: Private clinic - São Paulo (SP) - Brazil.
authors.forename: Juliana Ribeiro
authors.initials: JR
authors.lastname: Leitão
authors.affiliation: Hospital do Servidor Público Estadual de São Paulo (HSPE) - São Paulo (SP), Brazil.
authors.forename: Neusa Yuriko Sakai
authors.initials: NY
authors.lastname: Valente
authors.affiliation: Hospital do Servidor Público Estadual de São Paulo (HSPE) - São Paulo (SP), Brazil.
authors.forename: Priscila
authors.initials: P
authors.lastname: Kakizaki
authors.affiliation: Private clinic - São Paulo (SP) - Brazil.
authors.forename: Isis Suga
authors.initials: IS
authors.lastname: Veronez
authors.affiliation: Hospital do Servidor Público Estadual de São Paulo (HSPE) - São Paulo (SP), Brazil.|Hospital Padre Bento de Guarulhos - Guarulhos (SP), Brazil.
authors.forename: Mario Cezar
authors.initials: MC
authors.lastname: Pires
mesh_terms: D000505:Alopecia / Q000139:chemically induced / Q000473:pathology; D000970:Antineoplastic Agents / Q000009:adverse effects; D001706:Biopsy; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate / Q000009:adverse effects; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008010:Lichen Planus / Q000473:pathology*; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C498826:nilotinib